Enfamil NeuroPro Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-05

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare infant gut bacteria for infants who have been fed a standard infant formula (Enfamil Infant); infants who have been fed a new infant formula designed to be more similar to breast milk (Enfamil NeuroPro); and breastfed infants. These formulas are currently available on the market and meet FDA requirements for infant formula.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas

NCT04059666

Gastrointestinal Microbiome

TERMINATED NA

Exploratory/Proof of Principle Microbiota Study

NCT02500563

Fecal Microbiota

COMPLETED NA

Growing Up Formula Versus Nutritional Supplements: Effect on Catch up Growth, Micronutrient Status, and Solid Foods Intake in Toddlers With Mild or Moderate Malnutrition

NCT05088590

Healthy Toddlers 12-36 Months of Age With Mild or Moderate Malnutrition

COMPLETED NA

Feeding Tolerance and Gut Maturation of Infants Consuming a Formula Rich in Glycoprotein

NCT04880083

Digestion Gut Microbiota

COMPLETED NA

Growth of Infants Fed New Starter Formula

NCT01079208

Dietary Intervention

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized, double-blind, parallel-group study comparing breast milk to Enfamil Infant and Enfamil NeuroPro formulas. The central hypothesis of the study is that the addition of milk fat globule membrane and2'-Fucosyllactose (2'-FL) to infant formula plays a role in shaping the microbiota in a manner similar to the microbiota of breastfed infants. To test this hypothesis, the investigators will explore longitudinal changes in the fecal microbiome from birth to 4 months of age in infants fed breast-milk, standard Enfamil Infant formula or Enfamil NeuroPro formula. Fecal samples will be collected at birth, and then monthly for 4 months. At the time of last collection one serum sample will be collected. The investigators will analyze basic growth parameters, fecal microbial community analysis by metagenomics, fecal metabolome by untargeted metabolomic analysis, and fecal and systemic indicators of inflammation and intestinal barrier function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infant Development Infant ALL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects will be able to choose between the breast-fed or formula-fed group. Subjects in the formula-fed group will be randomly assigned to one of the two formulas, with a 50% chance of being assigned to each group.

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Participants and research nurse/coordinator will be blinded to the formula assignment. The formulas used will be a standard infant formula (Enfamil Infant) and a new infant formula designed to be more similar to breast milk (Enfamil NeuroPro); both formulas are available for purchase by the public and meet FDA requirements for infant formulas. Each formula can (identical size) will be relabeled and coded by the investigators. Participants in the formula group will be provided with a four-month supply of powdered formula at the time of discharge from the hospital, along with stool collection kits.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast Milk

Group Type NO_INTERVENTION

No interventions assigned to this group

Enfamil Infant

Group Type OTHER

Enfamil Infant

Intervention Type DIETARY_SUPPLEMENT

FDA Infant formula

Enfamil NeuroPro

Group Type ACTIVE_COMPARATOR

Enfamil NeuroPro

Intervention Type DIETARY_SUPPLEMENT

FDA Infant formula

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enfamil NeuroPro

FDA Infant formula

Intervention Type DIETARY_SUPPLEMENT

Enfamil Infant

FDA Infant formula

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy term infants with parental consent
* Parents are able to provide informed consent; own a smart phone and are able to fill out weekly digital questionnaires.

Exclusion Criteria

* Prematurity (\<= 36 weeks gestational age)
* Babies born through c-section
* Any health issues identified at the first postpartum screening
* Use of both breast milk and formula
* Use of donor breast milk
* Parent unwillingness/inability to avoid giving prebiotics, probiotics, symbiotics, and immune-stimulating products to the child for the duration of this study

Minimum Eligible Age

0 Months

Maximum Eligible Age

4 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes